TNF and inflammatory bowel disease: Among them, the proportion of UC/IBD-U patients under TNF-α inhibitors was similar in both cohorts (VEO-UC/IBD-U 60% vs. EO-UC/IBD-U 57.1%) whereas the proportion tended to be higher in EO-CD (75%) than VEO-CD (42.9%).